Medicare has initiated price negotiation for Botox (onabotulinumtoxinA) and 14 other high-cost drugs, marking the first wave of federal price-setting authority under the Inflation Reduction Act. While Botox's primary medspa use is cosmetic (and thus not Medicare-reimbursed), the negotiation signals broader regulatory intent to constrain toxin pricing across all channels.